Close Menu

NEW YORK – Antibody analysis firm Serimmune said on Friday that it has entered an agreement with biotech company Atreca around development of therapeutic antibodies for cancer.

Under the agreement, Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.

The SERA platform uses a combination of bacterial display peptide libraries, next-generation sequencing, and machine learning to identify antigens involved in antibody response.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.